Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ruben Raychaudhuri

Showing results (21-30 of 24) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 24 results.
Molecular Cancer Research : MCR|May 26, 2026
Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate CancerErolcan Sayar, Helen M Richards, Roman Gulati, et al.
Cancer Research Communications|August 6, 2025
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted TherapiesHyun Jung Lee, Roman Gulati, Erolcan Sayar, et al.
Clinical Genitourinary Cancer|January 11, 2025
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial CarcinomaRafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al.
Clinical Genitourinary Cancer|May 16, 2025
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology SubtypesDimitra Rafailia Bakaloudi, Rafee Talukder, Thomas Enright, et al.
Pageof 3

Showing results (21-30 of 24) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 24 results.
Molecular Cancer Research : MCR|May 26, 2026
Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate CancerErolcan Sayar, Helen M Richards, Roman Gulati, et al.
Cancer Research Communications|August 6, 2025
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted TherapiesHyun Jung Lee, Roman Gulati, Erolcan Sayar, et al.
Clinical Genitourinary Cancer|January 11, 2025
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial CarcinomaRafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al.
Clinical Genitourinary Cancer|May 16, 2025
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology SubtypesDimitra Rafailia Bakaloudi, Rafee Talukder, Thomas Enright, et al.
Pageof 3